Evidence supporting the use of: Alpha lipoic acid
For the health condition: Cirrhosis of the Liver

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha lipoic acid (ALA) is an antioxidant that has been studied for its potential hepatoprotective effects, including in the context of liver diseases such as cirrhosis. The rationale for its use hinges on its ability to scavenge free radicals, regenerate other antioxidants (like glutathione), and reduce oxidative stress, which plays a significant role in liver injury and the progression of cirrhosis. Several preclinical studies (in vitro and animal models) have shown that ALA can decrease liver enzyme levels, reduce fibrosis, and improve hepatic antioxidant defenses. There are also a limited number of small human studies and case reports suggesting that ALA may help improve liver function or reduce markers of oxidative stress in patients with liver disease, including cirrhosis and hepatitis.

However, the overall quality and quantity of clinical evidence are limited. Most human data comes from studies on acute liver failure (such as from mushroom poisoning), nonalcoholic fatty liver disease (NAFLD), or diabetes-related liver dysfunction rather than established cirrhosis. Large, randomized controlled trials specifically examining ALA for cirrhosis are lacking. Thus, while there is a clear scientific rationale and some promising preclinical and early clinical findings, robust evidence supporting its efficacy for cirrhosis management is currently insufficient. Therefore, the evidence rating is 2/5, reflecting weak but suggestive scientific support, and its use remains experimental rather than standard of care.

More about alpha lipoic acid
More about Cirrhosis of the Liver